DK2061510T3 - Treatment and / or prevention of Barrett's esophagus using anti-EphB4 antibody-containing compositions - Google Patents

Treatment and / or prevention of Barrett's esophagus using anti-EphB4 antibody-containing compositions Download PDF

Info

Publication number
DK2061510T3
DK2061510T3 DK07800240.9T DK07800240T DK2061510T3 DK 2061510 T3 DK2061510 T3 DK 2061510T3 DK 07800240 T DK07800240 T DK 07800240T DK 2061510 T3 DK2061510 T3 DK 2061510T3
Authority
DK
Denmark
Prior art keywords
antibody
ephb4
cancer
antibodies
treatment
Prior art date
Application number
DK07800240.9T
Other languages
Danish (da)
English (en)
Inventor
Antony William Scammell
Original Assignee
A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904752A external-priority patent/AU2006904752A0/en
Application filed by A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust filed Critical A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust
Application granted granted Critical
Publication of DK2061510T3 publication Critical patent/DK2061510T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK07800240.9T 2006-08-31 2007-08-31 Treatment and / or prevention of Barrett's esophagus using anti-EphB4 antibody-containing compositions DK2061510T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006904752A AU2006904752A0 (en) 2006-08-31 Uses for Antibodies
PCT/AU2007/001282 WO2008025099A1 (en) 2006-08-31 2007-08-31 Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions

Publications (1)

Publication Number Publication Date
DK2061510T3 true DK2061510T3 (en) 2016-09-05

Family

ID=39135433

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07800240.9T DK2061510T3 (en) 2006-08-31 2007-08-31 Treatment and / or prevention of Barrett's esophagus using anti-EphB4 antibody-containing compositions

Country Status (8)

Country Link
US (2) US20100297140A1 (OSRAM)
EP (1) EP2061510B1 (OSRAM)
JP (1) JP2010501596A (OSRAM)
CN (1) CN101626784B (OSRAM)
AU (1) AU2007291891B2 (OSRAM)
DK (1) DK2061510T3 (OSRAM)
NZ (1) NZ575918A (OSRAM)
WO (1) WO2008025099A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2244735A4 (en) 2007-10-02 2011-02-23 Avaxia Biologics Inc ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE
EP3461840A1 (en) 2009-04-27 2019-04-03 Immuron Limited Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of non alcoholic steatohepatitis
JP2011026252A (ja) * 2009-07-27 2011-02-10 Kitasato Institute 上皮成長因子受容体に対する卵黄抗体およびその用途
EP2605791B1 (en) 2010-08-17 2017-03-08 Immuron Limited Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
ES2742734T3 (es) 2010-11-23 2020-02-17 Pantheryx Inc Composiciones y procedimientos para el tratamiento en aplicaciones clínicas de espectro general, no diferenciadas o mixtas
TWI655210B (zh) * 2010-12-08 2019-04-01 艾伯維史坦森特瑞斯有限責任公司 新穎調節劑及其使用方法
WO2012098256A1 (en) * 2011-01-21 2012-07-26 Université De La Méditerranée Aix - Marseille Ii Anti-cd146 auto-antibodies and uses thereof
DE102011006809A1 (de) * 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
US20140017174A1 (en) * 2011-11-30 2014-01-16 Raja Atreya Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
BR112016010051A2 (pt) 2013-11-04 2017-12-05 Pfizer ?conjugados de anticorpo-fármaco anti-efna4?
RO130965A8 (ro) * 2015-10-16 2017-06-30 Romvac Company S.A. Producerea şi utilizarea oului hiperimun personalizat () în tratamentul psoriazisului
US10792320B2 (en) * 2018-03-28 2020-10-06 Michael Alan Beller Methods for treatment of bladder dysfunction
WO2020176637A1 (en) 2019-02-26 2020-09-03 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
US11319382B1 (en) 2021-06-28 2022-05-03 King Abdulaziz University Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911108A (en) * 1973-02-14 1975-10-07 Diamond Shamrock Corp Process of producing bovine milk products containing specific antibodies
AUPN642795A0 (en) * 1995-11-08 1995-11-30 Northfield Laboratories Pty Ltd Dairy compositions and methods of preparing same
AU729502B2 (en) * 1996-10-02 2001-02-01 Ovimmune, Inc. Oral administration of chicken yolk antibodies to treat disease
JP2002509109A (ja) * 1998-01-19 2002-03-26 ディーシーヴィー インコーポレイテッド 関節炎および／または自己免疫疾患を治療および予防するための組成物および方法
WO1999064069A1 (en) * 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
CN1163511C (zh) * 1999-10-22 2004-08-25 徐永华 鸡卵黄抗白细胞介素-8抗体、制备方法及其应用
CN1303889A (zh) 1999-12-20 2001-07-18 陶氏康宁东丽硅氧烷株式会社 用于嵌件模塑或双模腔模塑的硅橡胶组合物
JP2005298332A (ja) * 2000-09-28 2005-10-27 Shibayagi:Kk 過剰自己抗体産生抑制物質、その製造法およびその使用方法
KR20040106298A (ko) * 2002-03-21 2004-12-17 아나디스 리미티드 불안정한 생활성 물질 및 포유동물 초유를 포함한 조성물,제조 및 치료 방법
CN1199672C (zh) 2002-04-17 2005-05-04 李永忠 一套预防与治疗癌症中成药
CN1377894A (zh) * 2002-04-23 2002-11-06 郭占军 蛋黄抗癌抗体制备方法及其应用
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
JP4264894B2 (ja) * 2004-03-01 2009-05-20 三菱自動車工業株式会社 エアボックス付きグローブボックス
EP2275445A3 (en) * 2004-03-12 2012-02-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
JP2008518207A (ja) * 2004-10-21 2008-05-29 ザ ペン ステート リサーチ ファウンデーション Ｅｐｈ受容体腫瘍バイオマーカー
AU2006210837B2 (en) * 2005-01-31 2012-07-12 Genentech, Inc. Anti-EphB2 antibodies and methods using same
US20090306347A1 (en) 2005-08-29 2009-12-10 Japan Science And Technology Agency Antibody produced using ostrich and method for production thereof

Also Published As

Publication number Publication date
US8834872B2 (en) 2014-09-16
NZ575918A (en) 2012-03-30
US20100297140A1 (en) 2010-11-25
US20130295109A1 (en) 2013-11-07
CN101626784B (zh) 2013-07-17
AU2007291891A1 (en) 2008-03-06
EP2061510B1 (en) 2016-06-22
EP2061510A1 (en) 2009-05-27
EP2061510A4 (en) 2011-01-05
AU2007291891B2 (en) 2013-10-31
WO2008025099A1 (en) 2008-03-06
CN101626784A (zh) 2010-01-13
JP2010501596A (ja) 2010-01-21

Similar Documents

Publication Publication Date Title
US8834872B2 (en) Uses of antibodies
JP7342701B2 (ja) 癌の治療及び／又は予防用医薬組成物
JP6359492B2 (ja) 抗ＩＬ−１α抗体による癌の処置方法
TWI852695B (zh) 抗體-藥物結合物之用途
JP4854912B2 (ja) 癌に対する抗体
TW201815423A (zh) 免疫性／治療性聚醣組合物及其用途
BR112019008335A2 (pt) conjugado de um anticorpo, composição farmacêutica e método para o tratamento e/ou a prevenção de um câncer
TW201622743A (zh) 免疫原醣肽、包含該醣肽之組合物及其用途
JP2005508839A (ja) ペプチドおよびｍｕｃ１タンパク質に対する抗体
TWI843105B (zh) 抗her2 抗體藥物偶聯物在治療尿路上皮癌中的用途
WO2021182573A1 (ja) 癌の治療及び／又は予防のための医薬品
JP2022512709A (ja) 炎症性疾患及び自己免疫疾患を処置する組成物及び方法
JP2023553773A (ja) 抗ｈｍｍｗ抗体、それを含む組成物、及びそれをコードする核酸分子、並びにその使用
JP6997785B2 (ja) 炎症性障害の治療療法
TWI862564B (zh) 癌治療用醫藥
BRPI0717142A2 (pt) Composição terapêutica e kit de reativos para uso terapêutico
WO2019045025A1 (ja) ワクチン組成物
Cortés-Sarabia María Lilia Nicolás-Morales1, Víctor Manuel Luna-Pineda2, Carlos Alberto Serrano-Bello2, Miguel David Guerrero-Macedonio1, Cynthia Rodríguez-Nava1, Isela Parra-Rojas1, Mónica Espinoza-Rojo1, Eugenia Flores-Alfaro1, Luz del Carmen Alarcón-Romero1, Amalia Vences-Velázquez1✉ &
JP7202576B2 (ja) がんの予防および／または治療に利用するための抗プレセニリン抗体またはそのフラグメント
CN120795151A (zh) 抗犬pd-l1单克隆抗体及其在制备抗癌药物方面的应用
JP2011026252A (ja) 上皮成長因子受容体に対する卵黄抗体およびその用途
WO2020256110A1 (ja) タイトジャンクション形成誘導剤
EA006599B1 (ru) Способ повышения экспрессии опухолевого антигена с применением тималфазина